Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

AXL-1717 exhibits safety/tolerability in subjects with advanced tumors in phase I/II trial

April 8, 2011

Millenium Pharma and Sunesis Pharma enter agreement for kinase inhibitors in oncology

April 8, 2011

Progenra's ubiquitin carboxyl-terminal hydrolase inhibitors show preclinical antitumor activity

April 8, 2011

Progen Pharma completes enrollment in phase I trial of PG-11047

April 6, 2011

Phase II PX-866 trial in glioblastoma begins enrollment

April 6, 2011

New androgen receptor ligands described by Bayer Schering Pharma

April 6, 2011

Navitoclax enhances efficacy of taxanes in models of NSCLC

April 6, 2011

RRx-001 to enter clinic as chemotherapeutic/radiosensitizer for cancer

April 6, 2011

New PTEN/TP53/RB1 triple knockout model described of high-grade astrocytoma

April 6, 2011

MK-2206 advances to phase II testing in breast cancer

April 6, 2011

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...